Evidence map›Paper›PMID 40330837›Full record

ReviewPsoriasis (Auckland, N.Z.)2025

Challenges Psoriasis and Its Impact on Quality of Life: Challenges in Treatment and Management.

Małgorzata Ponikowska, Ercole Vellone, Michał Czapla, Izabella Uchmanowicz

Registry-linked trialAbstract readReview
In one paragraph

Review in Psoriasis (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07366268 (Evaluation of Topical Apremilast Nanoparticles in the Treatment of Plaque Psoriasis), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07366268 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of Topical Apremilast Nanoparticles in the Treatment of Plaque Psoriasis: Clinical, Histopathological and Immunohistochemical Study

TypeinterventionalSponsorAssiut UniversityRan2026 to 2028Enrolled36ConditionsPsoriasisArmsApremilast Nanoformula 0.3٪, betamethasone valerate 0.1% cream
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Małgorzata PonikowskaDivision of Clinical Trials and Registries, University Centre of General Dermatology and Oncodermatology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.
Ercole VelloneDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Michał CzaplaDepartment of Emergency Medical Service, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0002-4245-5420
Izabella UchmanowiczDepartment of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, Poland.ORCID 0000-0001-5452-0210

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis, a chronic inflammatory disease affecting approximately 3% of the global population, presents complex challenges that extend beyond its physical manifestations. This comprehensive review examines the multidimensional impact of psoriasis on patients' lives, encompassing physical, psychological, and social aspects. We analyze current therapeutic approaches, from traditional systemic treatments to cutting-edge biological therapies and emerging oral medications, evaluating their efficacy, limitations, and accessibility. The review explores how disease severity correlates with quality of life measures and psychological burden, noting the high prevalence of depression (20%), anxiety (21%), and suicidal ideation (0.77%) among affected individuals. However, emerging evidence suggests that clinical severity, as measured by PASI or BSA, does not always correlate with the psychoemotional burden experienced by patients, highlighting the need for a more comprehensive assessment of disease impact. We discuss the evolution of treatment strategies, highlighting recent developments in targeted therapies, including JAK inhibitors, particularly selective TYK2 inhibitors, and PDE4 inhibitors, which offer promising alternatives to traditional treatments. Additionally, we examine the role of various assessment tools and quality of life measures in evaluating treatment outcomes. The analysis emphasizes the need for a holistic approach to patient care that integrates medical interventions with psychological support, addressing both the visible and invisible burdens of the disease. This review underscores the importance of personalized treatment strategies that consider not only clinical efficacy but also patient preferences, accessibility, and long-term safety profiles.

Indexed as

biologicsPDE4 inhibitorspsoriasispsychological impactquality of lifesystemic treatmentstreatment challengesTYK2 inhibitors

Identifiers

PMID40330837
PMCPMC12052009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.